Expertise in
3
conditions

Emmanuel Seront

Icans
Strasbourg, FR 
Expertise in
3
conditions
Icans
Strasbourg, FR 
OverviewLocationsClinical Research

Overview

Emmanuel Seront practices in Strasbourg, France. Mr. Seront is highly rated in 3 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Renal Cell Carcinoma (RCC), Head and Neck Squamous Cell Carcinoma (HNSCC), Nephrectomy, and Cystectomy.

His clinical research consists of co-authoring 81 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

ICANS
Strasbourg, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Active_not_recruiting
Publish Date: November 03, 2023
Intervention Type: Drug
Study Drugs: Afatinib, Palbociclib, Monalizumab, Durvalumab, Niraparib, Rogaratinib
Study Phase: Phase 2
Phase I Study of LEE011plus Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase I Study of LEE011plus Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Terminated
Publish Date: January 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trials

81 Total Publications

Bone marrow scintigraphy as a prognostic marker of overall survival in mCRPC patients treated with Radium-223 dichloride.
Bone marrow scintigraphy as a prognostic marker of overall survival in mCRPC patients treated with Radium-223 dichloride.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Seront's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile